Publications by authors named "Laura Rosanò"

68Publications

Targeting endothelin 1 receptor-miR-200b/c-ZEB1 circuitry blunts metastatic progression in ovarian cancer.

Commun Biol 2020 Nov 13;3(1):677. Epub 2020 Nov 13.

Preclinical Models and New Therapeutic Agents Unit, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.

View Article and Find Full Text PDF
November 2020

Tumor Cellular and Microenvironmental Cues Controlling Invadopodia Formation.

Front Cell Dev Biol 2020 15;8:584181. Epub 2020 Oct 15.

Unit of Preclinical Models and New Therapeutic Agents, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.

View Article and Find Full Text PDF
October 2020

Endothelin-1 axis fosters YAP-induced chemotherapy escape in ovarian cancer.

Cancer Lett 2020 Nov 26;492:84-95. Epub 2020 Aug 26.

Preclinical Models and New Therapeutic Agents Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Regina Elena National Cancer Institute, Rome, Italy. Electronic address:

View Article and Find Full Text PDF
November 2020

Targeting Endothelin-1 Receptor/β-Arrestin-1 Axis in Ovarian Cancer: From Basic Research to a Therapeutic Approach.

Front Endocrinol (Lausanne) 2019 4;10:609. Epub 2019 Sep 4.

Preclinical Models and New Therapeutic Agents Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Regina Elena National Cancer Institute, Rome, Italy.

View Article and Find Full Text PDF
September 2019

β-arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer.

Nat Commun 2019 07 19;10(1):3196. Epub 2019 Jul 19.

Preclinical Models and New Therapeutic Agents Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Regina Elena National Cancer Institute, 00144, Rome, Italy.

View Article and Find Full Text PDF
July 2019

New insights into the regulation of the actin cytoskeleton dynamics by GPCR/β-arrestin in cancer invasion and metastasis.

Int Rev Cell Mol Biol 2019 13;346:129-155. Epub 2019 Apr 13.

Unit of Preclinical Models and New Therapeutic Agents, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. Electronic address:

View Article and Find Full Text PDF
February 2020

Methods to Investigate β-Arrestin-1/β-Catenin Signaling in Ovarian Cancer Cells.

Methods Mol Biol 2019 ;1957:393-406

Preclinical Models and New Therapeutic Agents Unit, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.

View Article and Find Full Text PDF
July 2019

New Routes in GPCR/β-Arrestin-Driven Signaling in Cancer Progression and Metastasis.

Front Pharmacol 2019 19;10:114. Epub 2019 Feb 19.

Unit of Preclinical Models and New Therapeutic Agents, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.

View Article and Find Full Text PDF
February 2019

Regulation of extracellular matrix degradation and metastatic spread by IQGAP1 through endothelin-1 receptor signalling in ovarian cancer.

Matrix Biol 2019 08 25;81:17-33. Epub 2018 Oct 25.

Unit of Preclinical Models and New Therapeutic Agents, IRCCS - Regina Elena National Cancer Institute, Rome, Italy. Electronic address:

View Article and Find Full Text PDF
August 2019

hMENA is a key regulator in endothelin-1/β-arrestin1-induced invadopodial function and metastatic process.

Proc Natl Acad Sci U S A 2018 03 8;115(12):3132-3137. Epub 2018 Feb 8.

Unit of Preclinical Models and New Therapeutic Agents, IRCCS, Regina Elena National Cancer Institute, 00144 Rome, Italy;

View Article and Find Full Text PDF
March 2018

Targeting endothelin-1 receptor/β-arrestin1 network for the treatment of ovarian cancer.

Expert Opin Ther Targets 2017 10 5;21(10):925-932. Epub 2017 Sep 5.

a Preclinical Models and New Therapeutic Agents Unit, Translational Research Functional Departmental Area , Regina Elena National Cancer Institute , Rome , Italy.

View Article and Find Full Text PDF
October 2017

Blocking endothelin-1-receptor/β-catenin circuit sensitizes to chemotherapy in colorectal cancer.

Cell Death Differ 2017 10 14;24(10):1811-1820. Epub 2017 Jul 14.

Preclinical Models and New Therapeutic Agents Unit, Regina Elena National Cancer Institute, Rome, Italy.

View Article and Find Full Text PDF
October 2017

Endothelin-1 receptor drives invadopodia: Exploiting how β-arrestin-1 guides the way.

Small GTPases 2018 09 3;9(5):394-398. Epub 2016 Oct 3.

a Preclinical Models and New Therapeutic Agents Unit, Translational Research Functional Departmental Area , Regina Elena National Cancer Institute , Rome , Italy.

View Article and Find Full Text PDF
September 2018

β-arrestin1 at the cross-road of endothelin-1 signaling in cancer.

J Exp Clin Cancer Res 2016 07 29;35(1):121. Epub 2016 Jul 29.

Preclinical Models and New Therapeutic Agents Unit, Translational Research Functional Departmental Area, Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144, Rome, Italy.

View Article and Find Full Text PDF
July 2016

Disrupting the endothelin and Wnt relationship to overcome chemoresistance.

Mol Cell Oncol 2015 Jul-Sep;2(3):e995025. Epub 2015 Jan 30.

Molecular Pathology Laboratory; Regina Elena National Cancer Institute ; Rome, Italy.

View Article and Find Full Text PDF
June 2016

Endothelin therapeutics in cancer: Where are we?

Am J Physiol Regul Integr Comp Physiol 2016 Mar 27;310(6):R469-75. Epub 2016 Jan 27.

Translational Research Functional Departmental Area, Regina Elena National Cancer Institute, Rome, Italy

View Article and Find Full Text PDF
March 2016

Endothelin-1/endothelin A receptor axis activates RhoA GTPase in epithelial ovarian cancer.

Life Sci 2016 Aug 8;159:49-54. Epub 2016 Jan 8.

Translation Research Functional Area, Regina Elena National Cancer Institute Rome, Italy. Electronic address:

View Article and Find Full Text PDF
August 2016

Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis.

Life Sci 2016 Aug 8;159:43-48. Epub 2016 Jan 8.

Translational Research Functional Departmental Area, Regina Elena National Cancer Institute, Rome, Italy. Electronic address:

View Article and Find Full Text PDF
August 2016

β-Arrestin 1 is required for endothelin-1-induced NF-κB activation in ovarian cancer cells.

Life Sci 2014 Nov 12;118(2):179-84. Epub 2014 Feb 12.

Laboratory of Molecular Pathology, Regina Elena National Cancer Institute, Rome, Italy. Electronic address:

View Article and Find Full Text PDF
November 2014

Endothelin 1 in cancer: biological implications and therapeutic opportunities.

Nat Rev Cancer 2013 Sep 25;13(9):637-51. Epub 2013 Jul 25.

Laboratory of Molecular Pathology A, Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome 00144, Italy.

View Article and Find Full Text PDF
September 2013

Beta-arrestin-1 mediates the endothelin-1-induced activation of Akt and integrin-linked kinase.

Can J Physiol Pharmacol 2010 Aug;88(8):796-801

Laboratory of Molecular Pathology, Regina Elena Cancer Institute, via Delle Messi D'Oro 156, Rome, Italy.

View Article and Find Full Text PDF
August 2010

The importance of endothelin axis in initiation, progression, and therapy of ovarian cancer.

Am J Physiol Regul Integr Comp Physiol 2010 Aug 10;299(2):R395-404. Epub 2010 Jun 10.

Molecular Pathology Laboratory, Regina Elena National Cancer Institute, Via delle Messi D'Oro 156, 00158 Rome, Italy.

View Article and Find Full Text PDF
August 2010

Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade.

Cancer Res 2009 Mar 10;69(6):2669-76. Epub 2009 Mar 10.

Molecular Pathology and Immunology Laboratories, Regina Elena Cancer Institute and Molecular Biology and Pathology Institute, National Research Council, Rome, Italy.

View Article and Find Full Text PDF
March 2009

Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis.

Proc Natl Acad Sci U S A 2009 Feb 6;106(8):2806-11. Epub 2009 Feb 6.

Laboratories of Molecular Pathology, Experimental Chemotherapy, and Immunology, Regina Elena Cancer Institute, 00158 Rome, Italy.

View Article and Find Full Text PDF
February 2009

The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy.

Can J Physiol Pharmacol 2008 Aug;86(8):473-84

Molecular Pathology and Ultrastructure Laboratory, Regina Elena Cancer Institute, Via delle Messi d'Oro 156, Rome, Italy.

View Article and Find Full Text PDF
August 2008

The endothelin axis in cancer.

Int J Biochem Cell Biol 2008 1;40(8):1443-51. Epub 2008 Feb 1.

Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Via delle Messi d'Oro 156, 00158 Rome, Italy.

View Article and Find Full Text PDF
July 2008

Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.

Cells Tissues Organs 2007 ;185(1-3):85-94

Molecular Pathology and Ultrastructure Laboratory, Regina Elena Cancer Institute, Rome, Italy.

View Article and Find Full Text PDF
July 2007

Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells.

Cancer Res 2007 Feb;67(4):1725-34

Laboratory of Molecular Pathology and Ultrastructure, Rome Oncogenomic Center, and Laboratory of Immunology, Regina Elena Cancer Institute, Via delle Messi d'Oro 156, 00158 Rome, Italy.

View Article and Find Full Text PDF
February 2007

Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma.

Mol Cancer Ther 2006 Jun;5(6):1483-92

Laboratory of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Via delle Messi d'Oro, 156, 00158 Rome, Italy.

View Article and Find Full Text PDF
June 2006

ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation.

Exp Biol Med (Maywood) 2006 Jun;231(6):1132-5

Molecular Pathology Laboratory, Regina Elena Cancer Institute, Via delle Messi d'Oro 156, 00158 Rome, Italy.

View Article and Find Full Text PDF
June 2006

Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression.

Exp Biol Med (Maywood) 2006 Jun;231(6):1128-31

Laboratory of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Via delle Messi D'Oro 156, 00158 Rome, Italy.

View Article and Find Full Text PDF
June 2006

Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma.

Mol Cancer Ther 2006 Apr;5(4):833-42

Laboratory of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Via delle Messi D'Oro 156, 00158 Rome, Italy.

View Article and Find Full Text PDF
April 2006

Emerging role of the endothelin axis in ovarian tumor progression.

Endocr Relat Cancer 2005 Dec;12(4):761-72

Molecular Pathology and Ultrastructure Laboratory, Regina Elena Cancer Institute, Rome, Italy.

View Article and Find Full Text PDF
December 2005

Endothelin-B receptor blockade inhibits molecular effectors of melanoma cell progression.

J Cardiovasc Pharmacol 2004 Nov;44 Suppl 1:S136-9

Laboratory of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Rome, Italy.

View Article and Find Full Text PDF
November 2004

Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion.

J Biol Chem 2004 Nov 3;279(45):46700-5. Epub 2004 Sep 3.

Laboratories of Molecular Pathology and Ultrastructure and Immunology, Regina Elena Cancer Institute, 00158 Rome, Italy.

View Article and Find Full Text PDF
November 2004

Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.

Clin Cancer Res 2004 Jul;10(14):4670-9

Laboratories of Molecular Pathology and Ultrastructure and Immunology, Regina Elena Cancer Institute, Rome, Italy.

View Article and Find Full Text PDF
July 2004

Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression.

Cancer Res 2004 Feb;64(4):1436-43

Laboratory of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Via delle Messi d'Oro 156, 00158 Rome, Italy.

View Article and Find Full Text PDF
February 2004

Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells.

J Biol Chem 2003 Oct 7;278(42):41294-301. Epub 2003 Aug 7.

Laboratories of Molecular Pathology and Ultrastructure and Immunology, Regina Elena Cancer Institute, Rome 00158, Italy.

View Article and Find Full Text PDF
October 2003

Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo.

Am J Pathol 2003 Aug;163(2):753-62

Laboratories of Molecular Pathology and Ultrastructure and Immunology, Regina Elena Cancer Institute, and the Molecular Biology and Pathology Institute, Consiglio Nazionale delle Ricerche, Rome, Italy.

View Article and Find Full Text PDF
August 2003

Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.

Cancer Res 2003 May;63(10):2447-53

Laboratories of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, 00158 Rome, Italy.

View Article and Find Full Text PDF
May 2003

ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro.

Clin Sci (Lond) 2002 Aug;103 Suppl 48:318S-321S

Laboratory of Molecular Pathology, Regina Elena Cancer Institute, Via delle Messi d'Oro 156, 00158 Rome, Italy.

View Article and Find Full Text PDF
August 2002

Endothelin-1 promotes proteolytic activity of ovarian carcinoma.

Clin Sci (Lond) 2002 Aug;103 Suppl 48:306S-309S

Laboratory of Molecular Pathology, Regina Elena Cancer Institute, Via delle Messi d'Oro 156, 00158 Rome, Italy.

View Article and Find Full Text PDF
August 2002

Endothelin-1 acts as a survival factor in ovarian carcinoma cells.

Clin Sci (Lond) 2002 Aug;103 Suppl 48:302S-305S

Experimental Chemotherapy Laboratory, Regina Elena Cancer Institute, Via delle Messi d'Oro 156, 00158 Rome, Italy.

View Article and Find Full Text PDF
August 2002

Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells.

J Biol Chem 2002 Aug 22;277(31):27850-5. Epub 2002 May 22.

Laboratory of Molecular Pathology, Regina Elena Cancer Institute, 00158 Rome, Italy.

View Article and Find Full Text PDF
August 2002